Designer Glycopeptides for Cytotoxic T Cell-based Elimination of Carcinomas

Journal of Experimental Medicine

Volumn 199, Issue 5, 2004, Pages 707-716

  Xu, Yanfei ^a   Gendler, Sandra J ^b   Franco, Alessandra ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Carcinomas; CTL; Glycopeptides; Immunotherapy; Tumor associated carbohydrate antigens

Indexed keywords

CANCER VACCINE; FREUND ADJUVANT; GLYCOPEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUCIN 1; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; THOMSEN FREIDENREICH ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; CARBOHYDRATE SEQUENCE; CROSS REACTIONS; DRUG DESIGN; FEMALE; GLYCOPEPTIDES; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 1542283702     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20031865     Document Type: Article

References (53)

1. Hakomori, S. 1989. Aberrant glycosylation in tumors and tumor associate carbohydrate antigens. Adv. Cancer Res. 52: 257-331.
2. Fung, P.Y.S., M. Madej, R.R. Koganty, and B.M. Longenecker. 1990. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res. 50:4308-4314.3.
3. Henningsson, C.M., S. Selvaraj, G.D. MacLean, M.K. Suresh, A.A. Noujaim, and B.M. Longenecker. 1987. T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo. Cancer Immunol. Immunother. 25:231-241.
4. Singhai, A., and S. Hakamori. 1990. Molecular changes in carbohydrate antigen associated with cancer. Biol. Assays. 12: 223-230.
5. Singhai, A., M. Fohn, and S. Hakamori. 1991. Induction of alpha-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res. 51:1406-1411.
6. Zhao, X.-J., and N.-K.V. Cheung. 1995. GD2 oligosaccharide: target for cytotoxic T lymphocytes. J. Exp. Med. 182: 67-74.
7. Madden, D.R., D.N. Garbogzi, and D.C. Wiley. 1993. The antigenic identify of peptide-MHC compexes: a comparison of the conformation of five viral peptides presented by HLA A2. Cell. 75:693-708.
8. Fremont, D.H., M. Matsumura, E.A. Stura, P.A. Peterson, and I.A. Wilson. 1992. Crystal structure of two viral peptides complex with murine class I H-2Kb. Science. 257:919-927.
9. Franco, A., T. Yokoyama, D. Huynh, C. Thomson, S. Nathenson, and H.M. Grey. 1999. Fine specificity and MHC restriction of trinitrophenyl-specific CTL. J. Immunol. 162: 3388-3394.
10. Eisen, H.N. 2001. Specificity and degeneracy in antigen recognition: yin and yang in the immune systhem. Annu. Rev. Immunol. 19:1-21.
11. Hafler, D.A. 2002. Degeneracy, as opposed to specificity, in immunotherapy. J. Clin. Invest. 109:641-649.
12. Schultze, J.L. 2002. Degeneracy instead of specificity: is this a solution to cancer immunotherapy? Trends Immunol. 23:343-344.
13. Springer, G.F. 1984. T and Tn, general carcinoma autoantigens. Science. 224:1198-1206.
14. Langkilde, N.C., H. Wolf, H. Clausen, T. Kjeldsen, and T.F. Orntoft. 1992. Nuclear volume and expression of T-antigen, sialosyl Tn antigen and Tn antigen in carcinoma of the human bladder. Cancer. 69:219-227.
15. Itzkowitz, S., M. Yuan, C.K. Montgomery, T. Kjeldsen, H.K. Takahashi, W.L. Bigbe, and Y.S. Kim. 1989. Expression of Tn, syalosyl Tn and T antigen in human colon cancer. Cancer Res. 49:197-204.
16. Hull, S.R., and K.L. Carraway. 1988. Mechanism of expression of Thomsen Freidereich (T) antigen at the cell surface of a mammary adenocarcinoma. FASEB J. 2:2380-2384.
17. MacLean, G.D., M.B. Bowen-Yacyshyn, J. Samuel, A. Meikle, G. Stuart, J. Nation, S. Poppema, M. Jerry, R.R. Koganty, T. Wong, et al. 1992. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J. Immunother. 11:292-305.
18. Stein, R., S. Chen, W. Grossman, and D.M. Goldenberg. 1989. Human lung carcinoma monoclonal antibody specific for the Thomsen-Friedenreich antigen. Cancer Res. 49:32-37.
19. Cao, Y., P. Stosiek, and G.F. Springer. 1996. Thomsen-Freidenreich-related carbohydrate antigens in normal adult tissues: a systemic and comparative study. Histochem. Cell Biol. 106:197-207.
20. Chen, Y.X., R.K. Jain, E.V. Chandrasekaran, and K.L. Matta. 1995. Use of sialyated derivatives and acrylamide copolymers of Gal (beta 1,3) Gal Nac alpha - to determine the specificities of blood group T- and Tn-specific lectines and the copolymers to measure anti-T and anti-Tn antibody levels in cancer patients. Glycoconj. J. 12:55-62.
21. Dahlenborg, K., L. Hultman, R. Carlsson, and B. Jansson. 1997. Human monoclonal antibodies specific for the tumor associated Thomsen-Friedenreich antigen. Int. J. Cancer. 70: 63-71.
22. O'Boyle, K.P., and K.E. Whrite. 1994. Anti-Tn human monoclonal antibodies generated following active immunization with partially desialylated ovine submaxillary mucin. Hum. Antibodies Hybridoma. 5:25-31.
23. O'Boyle, K.P., A.L. Markowitz, M. Khorshidi, P. Lalezari, B.M. Longenecker, K.O. Lloyd, S. Welt, and K.W. Wright. 1996. Specificity analysis of murine monoclonal antibodies reactive with Tn, Sialylated Tn, T and monosialylated (2→6) T antigens. Hybridoma. 15:401-408.
24. Gendler, S., J. Taylor-Papadimitriou, T. Duhig, J. Rothbard, and J. Burchell. 1988. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made of tandem repeats. J. Biol. Chem. 263:12820-12823.
25. Finn, O.J., K.R. Jerome, R.A. Henderson, G. Pecher, N. Domenech, J. Magarian-Blander, and S.M. Barratt-Boyes. 1995. MUC-1 epithelial tumor mucin-based immunity and cancer vacccines. Immunol. Rev. 145:61-69.
26. Dahiya, R., K.S. Kwak, J.C. Byrd, S. Ho, W.H. Yoon, and Y.S. Kim. 1993. Mucin synthesis and secretion in various human epithelial cancer cell lines that express the MUC-1 mucin gene. Cancer Res. 53:1437-1443.
27. Liu, X., J. Sejbal, G. Kotovich, R.R. Koganti, M.A. Reddish, L. Jackson, S.S. Gandi, A.J. Mendoca, and B.M. Longenecker. 1995. Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides. Glycoconj. J. 12: 607-617.
28. St. Hilaire, P.M., L. Cipolla, A. Franco, U. Tedebark, D.A. Tilly, and M. Meldal. 1999. Synthesis of T-antigen-containing glycopeptides as potential cancer vaccines. J. Chem. Soc. Perkin Trans. I. 1:3559-3564.
29. Hauschka, T.S., L. Weiss, B.A. Holdrige, T.L. Cudney, M. Zumpft, and J.A. Planisken. 1971. Karyotipic and surface features of murine TA3 carcinoma cells during immunoselection in mice and rats. J. Natl. Cancer Inst. 47:343-359.
30. Rowse, G.J., R.M. Tempero, M.L. Vanlith, M.A. Hollingsworth, and S.J. Gendler. 1998. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 58:315-321.
31. Shaeffer, E.B., A. Sette, D.L. Jhonson, M.C. Bekoff, J.A. Smith, H.M. Grey, and S. Buus. 1989. Relative contribution of "determinant selection" and "holes in the T cell repertoire" to T cell responses. Proc. Natl. Acad. Sci. USA. 86: 4649-4653.
32. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W.M. Kast, C.J. Melief, C. Oseroff, L. Yuan, J. Ruppert, et al. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 143:5586-5592.
33. Falk, K., O. Rotzschke, S. Stevanovi, G. Jung, and H.-G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 351:290-296.
34. Boehncke, W.-H., T. Takeshita, C.D. Pendleton, R.A. Houghten, S. Sadegh-Nasseri, L. Racioppi, J.A. Berzofsky, and R.N. Germain. 1993. The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecules interactions and T cell recognition. J. Immunol. 150:331-341.
35. Ruppert, J., J. Sidney, E. Celis, R.T. Kubo, H.M. Grey, and A. Sette. 1993. Prominent role of secondary anchor residues in peptide binding to HLA A2. 1 molecule. Cell. 74:929-937.
36. Sette, A., J. Sidney, M.F. del Guercio, S. Southwood, J. Ruppert, C. Dahlberg, H.M. Grey, and R.T. Kubo. 1994. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol. Immunol. 31:813-822.
37. Jensen, T., M. Nielsen, M. Gad, P. Hansen, S. Komba, M. Meldal, N. Odum, and O. Werdefiin. 2001. Radically altered T cell receptor signaling in glycopeptide-specific T cell hybridoma induced by antigens with minimal differences in the glycan group. Eur. J. Immunol. 31:3197-3206.
38. Jansson, B., and C.A. Borrebaeck. 1992. The human repertoire of antibody specificities against Thomsen-Freidenreich and Tn-carcinoma-associated antigens as defined by human monoclonal antibodies. Cancer Immunol. Immunother. 34:294-298.
39. Franco, A., D.A. Tilly, I. Gramaglia, M. Croft, L. Cipolla, M. Meldal, and H.M. Grey. 2000. Epitope affinity for MHC class I determines helper requirement for CTL priming. Nat. Immunol. 1:145-150.
40. Ochsenbein, A.F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R.M. Zinkernagel. 2001. Roles of tumor localization, second signals and cross-priming in cytotoxic T cell induction. Nature. 411:1058-1064.
41. Sette, A., M. Newman, B. Livingston, D. McKinney, J. Sidney, G. Ishioka, S. Tangri, J. Alexander, J. Fikes, and R. Chestnut. 2002. Optimization vaccine design for cellular processing, MHC binding and TcR recognition. Tissue Antigens. 59:443-451.
42. Haurum, J.S., G. Arsequell, A.C. Lellouch, S.Y.C. Wong, R.A. Dweck, A.J. McMichael, and T. Elliott. 1994. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J. Exp. Med. 180:739-743.
43. Otvos, L., G.R. Krivulka, L. Urge, G.I. Szendrei, L. Nagy, Z.Q. Xiang, and H.C.J. Ertl. 1995. Comparison of the effects of amino acid substitutions and beta-N- vs. alpha-O-glycosylation on the T cell stimulatory activity and conformation of an epitope on the rabies virus glycoprotein. Biochim. Biophys. Acta. 1267:55-64.
44. Haurum, J.S., I.B. Hoier, G. Arsequell, A. Neisig, G. Valencia, J. Zeuthen, J. Neefjes, and T. Elliott. 1999. Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J. Exp. Med. 190:145-150.
45. Ferris, R.L., C. Hall, N.V. Sipsas, J.T. Safrit, A. Trocha, R.A. Koup, R.P. Johnson, and R.F. Siliciano. 1999. Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization. J. Immunol. 162:1324-1332.
46. Hudrisier, D., J. Riond, H. Mazarguil, and E. Gairing. 2001. Pleiotropic effects of post-translational modifications on the fate of viral glycopeptides as cytotoxic T cell epitopes. J. Biol. Chem. 12:38255-38260.
47. Abdel-Motal, U.M., L. Berg, A. Rosen, M. Bengtsson, C.J. Thorpe, J. Kihlberg, J. Dahmen, G. Magnusson, K.A. Karlsson, and M. Jondal. 1996. Immunization with glycosylated Kb-binding peptides generates carbohydrate-specific, unrestricted cytotoxic T cells. Eur. J. Immunol. 26:544-551.
48. Corinti, S., R. De Palma, A. Fontana, C. Gagliardi, C. Pini, and F. Sallusto. 1997. Major hystocompatibility complex-independent recognition of a distinctive pollen antigen, most likely a carbohydrate, by human CD8 α/β T cells. J. Exp. Med. 186:899-908.
49. Gendler, S., C. Lancaster, J. Taylor-Papadimitriou, T. Duhing, N. Peat, J. Burchell, L. Pemberton, E.-N. Lalani, and D. Wilson. 1990. Molecular cloning and expression of tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 265: 15286-15293.
50. Jerome, K.R., and O.J. Finn. 1993. Tumor-specific cytotoxic T cell clones from paptients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J. Immunol. 151:1654-1662.
51. Ioannides, C.G., B. Fisk, K.R. Jerome, T. Irimura, J.T. Wharton, and O.J. Finn. 1993. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 151:3693-3703.
52. Goydos, J.S., E. Elder, T.L. Whiteside, O.J. Finn, and M.T. Lotze. 1996. A phase I trail of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63:298-304.
53. Vlad, A.M., S. Muller, M. Cudic, H. Paulsen, L. Otvos, Jr., F.G. Hanisch, and O.J. Finn. 2002. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major hystocompatibility complex class II-restricted T cells. J. Exp. Med. 196:1435-1446.